- $4.09bn
- $3.45bn
- 34
- 19
- 57
- 30
Annual income statement for Immunovant, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 66.1 | 108 | 156 | 218 | 283 |
| Operating Profit | -66.1 | -108 | -156 | -218 | -283 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -66.3 | -108 | -157 | -211 | -259 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -66.4 | -107 | -157 | -211 | -259 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -66.4 | -107 | -157 | -211 | -259 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -66.4 | -107 | -157 | -211 | -259 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.54 | -1.22 | -1.43 | -1.66 | -1.82 |